John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cisco
CSCO
|
+$226M |
| 2 |
JPMorgan Chase
JPM
|
+$212M |
| 3 |
TSMC
TSM
|
+$204M |
| 4 |
Occidental Petroleum
OXY
|
+$194M |
| 5 |
Apple
AAPL
|
+$180M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$271M |
| 2 |
Microsoft
MSFT
|
+$267M |
| 3 |
Canadian Pacific Kansas City
CP
|
+$255M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$226M |
| 5 |
Coca-Cola
KO
|
+$225M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.48% |
| 2 | Healthcare | 15.21% |
| 3 | Industrials | 10.23% |
| 4 | Consumer Discretionary | 10.15% |
| 5 | Financials | 9.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
626
Hyliion Holdings
HYLN
$570M
| $9.2M | 0.03% |
2,075,593
+506,391
| +32% | +$2.24M |
|
627
Fidelity National Financial
FNF
$12.7B
| $9.13M | 0.03% |
194,443
-703,345
| -78% | -$33.6M |
|
628
Stem
STEM
$52.2M
| $9.13M | 0.03% |
+41,466
| New | +$9.65M |
|
|
GRP.U
629
DELISTED
Granite Real Estate Investment Trust
GRP.U
| $9.13M | 0.03% |
118,337
+27,600
| +30% | +$2.1M |
|
630
Impinj
PI
$4.88B
| $9.12M | 0.03% |
143,452
-16,416
| -10% | -$1.19M |
|
|
IS
631
DELISTED
ironSource Ltd.
IS
| $9.1M | 0.03% |
+1,896,553
| New | +$11.5M |
|
632
Stride
LRN
$3.57B
| $9.1M | 0.03% |
250,504
+235,483
| +1,568% | +$7.82M |
|
633
Genworth Financial
GNW
$3.74B
| $8.97M | 0.03% |
2,374,120
+2,202,548
| +1,284% | +$8.84M |
|
634
Evolent Health
EVH
$529M
| $8.95M | 0.03% |
277,224
+58,706
| +27% | +$1.54M |
|
|
CPRX
635
DELISTED
Catalyst Pharmaceutical
CPRX
| $8.91M | 0.03% |
1,075,282
+314,203
| +41% | +$2.22M |
|
636
Barings BDC
BBDC
$984M
| $8.89M | 0.03% |
859,674
+539,316
| +168% | +$5.78M |
|
637
Monro
MNRO
$396M
| $8.88M | 0.03% |
200,274
+182,902
| +1,053% | +$8.92M |
|
|
CHS
638
DELISTED
Chicos FAS, Inc.
CHS
| $8.85M | 0.03% |
1,844,575
+583,223
| +46% | +$2.73M |
|
639
CVS Health
CVS
$119B
| $8.82M | 0.03% |
87,103
-89,497
| -51% | -$9.4M |
|
640
Global Ship Lease
GSL
$1.6B
| $8.82M | 0.03% |
309,428
-72,972
| -19% | -$1.91M |
|
641
Codexis
CDXS
$185M
| $8.81M | 0.03% |
427,395
-233,641
| -35% | -$4.84M |
|
|
EVBG
642
DELISTED
Everbridge, Inc. Common Stock
EVBG
| $8.8M | 0.03% |
201,600
-136,780
| -40% | -$6.46M |
|
643
Vertex Pharmaceuticals
VRTX
$139B
| $8.78M | 0.03% |
+33,644
| New | +$7.98M |
|
644
Graco
GGG
$13.1B
| $8.74M | 0.03% |
125,359
-199,589
| -61% | -$14.4M |
|
|
KZR
645
DELISTED
Kezar Life Sciences
KZR
| $8.74M | 0.03% |
52,577
+2,625
| +5% | +$377K |
|
646
International Money Express
IMXI
$428M
| $8.73M | 0.03% |
423,799
+408,429
| +2,657% | +$7.02M |
|
647
NovoCure
NVCR
$1.96B
| $8.7M | 0.03% |
105,048
-286,939
| -73% | -$21.1M |
|
|
NBP
648
NovaBridge Biosciences American Depositary Shares
NBP
$219M
| $8.7M | 0.03% |
535,596
+417,060
| +352% | +$10.7M |
|
649
Allogene Therapeutics
ALLO
$719M
| $8.69M | 0.03% |
954,164
+764,373
| +403% | +$7.96M |
|
650
State Street SPDR S&P Oil & Gas Exploration & Production ETF
XOP
$3.77B
| $8.63M | 0.03% |
64,124
+42,770
| +200% | +$4.92M |
|
Similar funds
John Overdeck's Q1 2022 Portfolio in Review
As of Q1 2022, John Overdeck held 4,846 positions worth $33.9B, down 28% from $46.8B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
John Overdeck withdrew a net $11.3B in Q1 2022, closing 2,304 positions and reducing 976 holdings. Its most notable exit was Pfizer, an estimated $271M position sold in full.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 17% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, John Overdeck opened a new position in Cisco worth $223M.
- John Overdeck's largest Q1 2022 buy was Cisco: 4,001,362 shares worth $223M.
- John Overdeck added most to JPMorgan Chase in Q1 2022, an estimated $212M increase.
- John Overdeck's biggest Q1 2022 reduction was Coca-Cola, cutting an estimated $225M.
- John Overdeck fully exited Pfizer in Q1 2022, selling an estimated $271M.
- John Overdeck's ten largest holdings make up 7.2% of its $33.9B portfolio in Q1 2022.
- John Overdeck opened 656 new positions and closed 2,304 in Q1 2022.
- John Overdeck's portfolio value fell 28% quarter-over-quarter to $33.9B.
Based on Two Sigma Investments's 13F filing for Q1 2022, filed 16 May 2022.